Kevin Eggan, PhD
Group Vice President, Head of Research and Early Development, BioMarin, Principal Investigator, Professor
PhD, Massachusetts Institute of Technology
Dr. Eggan is a founding member of NYSCF’s Medical Advisory Board. He served as a tenured Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Director of Stem Cell Biology for the Stanley Center for Psychiatric Research at the Broad Institute, and an Institute Member of the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard. He is currently Group Vice President, Head of Research and Early Development at BioMarin.
Dr. Eggan earned a B.S. degree in microbiology and immunology from the University of Illinois and a Ph.D. in biology from MIT, where he focused on cloning, stem cells and reprogramming after nuclear transfer under the guidance of genetics pioneer Rudolf Jaenisch, Ph.D. He remained in the Jaenisch lab for a one-year post-doctoral position at the Whitehead Institute for Biomedical Research, where he conducted a study with Nobel laureate Richard Axel, M.D.
Dr. Eggan has published 130 scientific articles and holds 13 patents. He received the MacArthur Foundation’s “Genius Grant” and was named one of 50 Howard Hughes Medical Institute Early Career Scientists, among other distinctions. In addition, Dr. Eggan has served on the Scientific Advisory Boards of Ipierian, Roche and Angelini Pharma.
- NYSCF Community Shares Exciting Progress at International Society for Stem Cell Research Conference
- Promising Results Published on a New ALS Drug Discovered with NYSCF Support
- Precision Medicine and the Power of Stem Cells: Highlights of the 2019 NYSCF Conference
- NYSCF-Supported Research Leads to Successful Phase 2 Clinical Trial for ALS
- Translational Research Takes Center Stage at NYSCF Conference
- Researchers Uncover Clue to Brain Abnormalities in Schizophrenia
- Four NYSCF Innovators Featured In Nature Article on Embryonic Stem Cell Research
- NYSCF-Supported ALS Research Identifies Promising New Biological Pathway